Literature DB >> 12010104

Preventive stent placement for renal artery stenosis prior to emergent coronary artery bypass grafting.

Antonio E Martin-Ucar1, Ramesh L Patel.   

Abstract

PURPOSE: To illustrate the benefits of treating severe renal artery stenosis in renally compromised patients prior to surgery for coronary artery disease. CASE REPORT: A 63-year-old woman with unstable angina, severe coronary artery disease, and long-term severe renal impairment with a single functioning kidney underwent renal stent placement for high-grade renal artery stenosis prior to coronary artery surgery. The procedure improved her serum creatinine from 528 micromol/L at baseline to 385 micromol/L, and she subsequently underwent coronary artery bypass grafting without deterioration in her renal function. At 1 year, the patient has a serum creatinine of 400 micromol/L, and there is no evidence of in-stent stenosis.
CONCLUSIONS: Percutaneous renal angioplasty or stenting prior to coronary surgery in patients with concomitant renal and coronary artery disease may reduce perioperative renal deterioration in this specific group of patients.

Entities:  

Mesh:

Year:  2002        PMID: 12010104     DOI: 10.1177/152660280200900214

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  3 in total

1.  Multisystem revascularization.

Authors:  Zehra Jaffery; Arthur Grant
Journal:  Ochsner J       Date:  2009

2.  Peripheral vascular disease endovascular management in patients scheduled for cardiac surgery: a clinical-angiographic approach.

Authors:  Gianluca Rigatelli; Paolo Cardaioli; Massimo Giordan; Loris Roncon; Giuseppe Faggian; Giorgio Rigatelli; Pietro Zonzin
Journal:  Int J Cardiovasc Imaging       Date:  2006-03-09       Impact factor: 2.357

3.  The association between atherosclerotic renal artery stenosis and acute kidney injury in patients undergoing cardiac surgery.

Authors:  Jingang Yang; Changlin Lu; Li Yan; Xinran Tang; Wei Li; Yuejin Yang; Dayi Hu
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.